CNS & Neurological Disorders-Drug Targets

Papers
(The H4-Index of CNS & Neurological Disorders-Drug Targets is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Meet the Editorial Board Member113
Meet the Regional Editor75
Neurobiology of Amphetamine use in Stroke Recovery Combined with Rehabilitative Training and Brain Stimulation64
Na+/HCO3− Co-transporters Inhibitor S0859 Attenuates Global Cerebral Ischemia-reperfusion Injury of the CA1 Neurons in the Gerbil’s Hippocampus61
Targeting JNK3: An In-silico Approach to Uncover Potential Therapeutics for Alzheimer's Disease60
Recent Trends in Physical Therapy Interventions and Neuromodulation Techniques to Improve Neurorehabilitation38
The Natural Neuroprotective Compounds Used in the 6-Hydroxydopamine- Induced Parkinson’s Disease in Zebrafish: The Current Applications and Perspectives37
CRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer's Disease Treatment36
Memory Reflections of the Microbiota-Gut and Oligodendrocyte Axis36
Hypomyelination with Atrophy of Basal Ganglia and Cerebellum (HABC) Due to UFM1 Mutation in Roma Patients - Severe Early Encephalopathy with Stridor and Severe Hearing and Visual Impairment. A Single 34
The Potential Effect of Blueberry on Cognitive Health and Mood State based on Human Intervention Studies: Systematic Review and Mini Meta-Analysis32
Emerging Nanotechnology for the Treatment of Alzheimer’s Disease31
The Emerging Role of Marine Natural Products for the Treatment of Parkinson’s Disease30
Breaking Barriers: Advanced Pharmacological Mediators for Neuropsychiatric Disorders30
Unravelling the Role of Tyrosine and Tyrosine Hydroxylase in Parkinson’s Disease: Exploring Nanoparticle-based Gene Therapies29
Recent Advancement of Pyrazole Scaffold Based Neuroprotective Agents: A Review28
Unraveling the Triad: A Bioinformatics Analysis of the Interplay between Prenatal Depression, Inflammation, and the Gut Microbiota28
Cholinesterase Inhibitory and In Silico Toxicity Assessment of Thirty-Four Isoquinoline Alkaloids - Berberine as the Lead Compound25
GFAP and UCHL1 in Non-traumatic SAH: The Story thus Far. A Systematic Review of the Literature25
Pathological Insights into Neurodegenerative and Neurodevelopmental Disorders: Perspectives for the Development of Novel Treatment Approaches25
Monoamine Oxidase: A Potential Link in Papez Circuit to Generalized Anxiety Disorders24
Insights into the Diagnosis, Treatment, and Management of Prion Diseases24
Microbiota-Gut-Brain Axis: A Novel Paradigm in the Neurobiology of Anxiety23
0.083338975906372